IGHE and conjunctivitis: In particular, there was high risk of conjunctivitis in patients with severe AD prior to initiation of treatment, and high frequency in cases of prior conjunctivitis or increased thymus and activation-regulated chemokines, IgE, or eosinophils before initiation of treatment45–47.